Biotechnology

First U.S. Patent Issues on Hancock Jaffe VenoValve

April 7, 2021 1:40 PM

IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841. The company recently announced that only twenty-eight (28)...

Read more

CELFULL Celebrates its 20th Anniversary with a New Journey on the Way

April 7, 2021 9:30 AM

The anti-aging company CELFULL was founded in 2001 and will celebrate its 20th anniversary on April 18, 2021. CORAL SPRINGS, FL / ACCESSWIRE / April 7, 2021 / CELFULL is a brand of Puressence Biotech (USA) Inc. and dates back to 2001.The theme of the company's 20th anniversary is "Make a difference with your life". The anniversary slogan is based on the company's slogan "Restore Life Vitality". The company looks back on 20 years of...

Read more

Chattahoochee Labs/HeliosDx Announces Record Setting First Quarter

April 7, 2021 8:00 AM

ALPHARETTA, GA / ACCESSWIRE / April 7, 2021 / RushNet, Inc. (OTC PINK:RSHN), ("the Company") recently acquired and D/B/A Chattahoochee Labs/HeliosDx, is pleased to announce a record-setting first quarter with total revenues of $1,252,000. The first quarter proved challenging on many fronts. As previously noted, we expanded our testing capacity, as well as our testing capabilities. This process commenced in Q4 2020, but the bulk of the work and...

Read more

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells(R) to Treat COVID-19

April 6, 2021 1:45 PM

GOLDEN, CO / ACCESSWIRE / April 6, 2021 / Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-2a, randomized, double-blinded, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy...

Read more

Capstone Therapeutics Corp. Announces Transaction with Diamond Products Holdings, LLC

April 6, 2021 12:30 PM

Capstone Subsidiary Issues Debt to Acquire Equity Interest in Operating Company ALSIP, IL / ACCESSWIRE / April 6, 2021 / On March 31, 2021, the Company, through its relationship with Brookstone Partners (New York), executed definitive documents and acquired a minority interest in a consumer products company, Diamond Products, LLC ("Diamond"), a sexual wellness holding company. The transaction is based on the following...

Read more

Viewpoint Molecular Targeting(TM) Announces Strategic Partnership with Eichrom Technologies to Accelerate Isotope Production Process Development

April 6, 2021 10:00 AM

Automation of Manufacturing Is Critical to Scaling Viewpoint’s Isotope Production Technologies in a Way That Is Safe for Personnel and Cost Effective CORALVILLE, IA / ACCESSWIRE / April 6, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has established a strategic...

Read more

Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets

April 6, 2021 7:05 AM

Undertaking new 2021 R&D programs in additional drug markets with combined market potential of $87 Billion. KELOWNA, BC / ACCESSWIRE / April 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, will begin important new applied research and development (R&D) study programs planned in 2021. Lexaria's new study programs will target four drug...

Read more

Protera Appoints Novozymes Executive Thomas Videbaek As Chair of the Board of Directors and Non-Executive Board Member

April 6, 2021 2:00 AM

SANTIAGO, CHILE and PARIS, FRANCE / ACCESSWIRE / April 6, 2021 / Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced today it has appointed Novozymes senior executive Thomas Videbaek as Chair of the Board of Directors and non-executive board member. Dr. Videbaek has spent the last 13 years on the executive team at Novozymes, the world leader in...

Read more

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients

April 6, 2021 1:00 AM

First Study of Ensovibep in Patients With Symptomatic COVID-19 Disease Designed To Evaluate Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep Ensovibep Is Additionally Planned To Be Tested in Two Global, Placebo Controlled, Double Blinded Trials: A Phase 2–3 Trial in an Ambulatory Patient Setting (Named EMPATHY), and a Phase 3 Trial in a Hospitalized Patient Setting Sponsored by the NIH...

Read more

Applied UV, Inc. Appoints Mike Riccio as Chief Financial Officer

April 5, 2021 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / April 5, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that Mike Riccio, CPA, is appointed Chief Financial Officer, effective April 5,...

Read more

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

April 5, 2021 7:30 AM

IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to begin the U.S. pivotal trial for the VenoValve®. The VenoValve is an implantable valve designed to restore proper directional blood flow for...

Read more

FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients

April 5, 2021 2:00 AM

FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS OTTAWA, ON / ACCESSWIRE / April 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that the U.S. Food...

Read more

Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director

April 3, 2021 1:20 PM

GOLDEN, CO / ACCESSWIRE / April 3, 2021 / Vitro Biopharma, Inc. (formerly Vitro Diagnostics, Inc.) announced the appointment of Dr. Caroline Mosessian, PhD, DRSc, FACMPE, ACHE as its acting Director of Regulatory Affairs. Dr. Mosessian has an extensive background in regulatory science including a PhD, MS and Masters in Healthcare Administration degrees from USC in LA. In 2016 she was honored with the prestigious Top Ranked US Executive Award...

Read more

ProCell Surgical Inc. Awarded Breakthrough Technology Agreement With Premier

April 1, 2021 5:00 AM

CANTON, MA / ACCESSWIRE / April 1, 2021 / ProCell Surgical Inc. has been awarded a group purchasing agreement for Breakthrough Technology with Premier. Effective April 1, 2021, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Perfusion Products. "ProCell Surgical is delighted to have received a Breakthrough Technology Agreement with Premier for our...

Read more

Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada

April 1, 2021 2:00 AM

Tetra Bio-Pharma Inc. receives a Notice of Compliant rated inspection to distribute pharmaceuticals Key milestone in the development path to commercialization of Reduvo OTTAWA, ON / ACCESSWIRE / April 1, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have received a notice of compliance for its Drug...

Read more

Capstone Therapeutics Announces Operating Results for Fiscal 2020 - Including a Change in Its Deferred Tax Valuation Allowance

March 31, 2021 4:00 PM

ALSIP, IL / ACCESSWIRE / March 31, 2021 / Capstone Therapeutics (OTCQB:CAPS) ("the Company") today filed its Annual Report for the year ended December 31, 2020 with the OTCQB at www.OTCIQ.com. Net income attributable to Capstone Therapeutics Corp. stockholders totaled $8.5 million or $107.59 per share. Net income attributable to Capstone Therapeutics Corp. stockholders included a Federal income tax benefit of $8.7 million or $109.48 per share...

Read more

The Cannabis Science Inc., Share Exchange is Underway! OMNICANNA Files Name Change to Thermic Science International Corporation and Files SPAC Share Structure to Bring Cannabis Science and Recent Acquisition Companies to Begin Trading for All Thermic/ENDO Shareholders!

March 31, 2021 3:00 PM

NASHVILLE, TN / ACCESSWIRE / March 31, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097, OTC ENDO), is pleased to announce the company has successfully completed its name change to Thermic Science International Corporation. The company is equally proud to announce that the new share class has been created for the Cannabis Science share exchange...

Read more

BioLargo 2020 Annual Report Highlights Expanding Commercial Traction for its Cleantech Technologies, Record Revenue Growth and Improved Balance Sheet

March 31, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / March 31, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-K with the SEC today for the year ended December 31, 2020 (www.biolargo.com/sec-filings). The company has provided highlights from the Annual Report along with commentary on the recent advancements in its mission to "make life better"...

Read more

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

March 31, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Company's landmark Phase I trial to evaluate Pritumumab ("PTB") as a...

Read more

Dyadic Reports 2020 Year End Results and Recent Company Progress

March 30, 2021 4:00 PM

Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial  To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization To serve as proof of concept for next-generation multivalent COVID-19 vaccine candidates Expanded Korea and Southeast Asia vaccine development partnership with Medytox (086900) (KOSDAQ) focused on next-generation COVID-19 variant...

Read more